Chennai: Animal trials of Bharat Biotech International Limited’s Covid-19 vaccine candidate, Covaxin, have been successful and the results showed the shot’s ‘remarkable immunogenicity and protective efficacy’ in the Phase I clinical trials in India, the drugmaker has said.
Bharat Biotech tweeted, “Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in a live viral challenge model”.
Covaxin, developed by the Indian Council of Medical Research (ICMR) and Bharat Biotech, is being tested at 12 institutes across India.
The Hyderabad-based firm said the data from the study on primates substantiate the immunogenicity of the vaccine candidate.